Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 18 (1), 83-91

Megestrol Acetate Plus Low-Dose Estrogen in the Management of Advanced Prostatic Carcinoma

Affiliations
  • PMID: 1825145

Megestrol Acetate Plus Low-Dose Estrogen in the Management of Advanced Prostatic Carcinoma

J Geller. Urol Clin North Am.

Abstract

Megestrol acetate plus low-dose estrogen may be an effective, low-cost alternative to pharmacologic or surgical castration plus flutamide in the management of patients with advanced prostate cancer. The potential benefit of combined androgen ablation achieved by any means in comparison with conventional hormonal therapy appears to be limited.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

  • Hormonal Therapy for Stage D Cancer of the Prostate
    MR Gudziak et al. West J Med 160 (4), 351-9. PMID 8023485. - Review
    Adenocarcinoma of the prostate is the most common malignant neoplasm occurring in men. About half of patients present with metastatic disease. The mainstay of the treatme …

MeSH terms

LinkOut - more resources

Feedback